These are top 10 stocks traded on the Robinhood UK platform in July
Investing.com - Chardan Capital Markets maintained its buy rating and $82.00 price target on CRISPR Therapeutics (NASDAQ:CRSP) stock on Thursday. Currently trading at $46.61, the stock has shown strong momentum with a 16% gain over the past six months. According to InvestingPro data, analyst targets for CRSP range from $32 to $268, reflecting diverse views on the company’s potential.
The research firm cited Eli Lilly (NYSE:LLY)’s recent acquisition of Verve Therapeutics as a positive signal for gene editing therapies in the cardiovascular space. Lilly agreed to purchase Verve for $1 billion in upfront cash, with potential additional payments bringing the total to approximately $1.3 billion including contingent value rights. InvestingPro analysis shows CRISPR maintains a strong financial position, with more cash than debt on its balance sheet and a healthy current ratio of 15.6x.
Chardan noted that while some investors have questioned the market demand for one-time gene editing therapies in cardiovascular applications, Lilly’s acquisition represents "a vote of confidence in the approach from an established CV player with programs leveraging other modalities for similar targets."
The firm believes CRISPR Therapeutics’ growing presence in the cardiovascular space could drive further valuation upside for the company. This assessment comes as CRISPR continues to develop its gene editing technology for various therapeutic applications.
CRISPR Therapeutics has been expanding its pipeline beyond its initial focus areas, positioning itself as what Chardan describes as "a credible player" in the cardiovascular treatment landscape. With a market capitalization of $4.3 billion, CRISPR shows promising potential despite current unprofitability. For deeper insights into CRISPR’s valuation and growth prospects, investors can access comprehensive Pro Research Reports available exclusively on InvestingPro, which provides detailed analysis of the company’s financial health and market position.
In other recent news, CRISPR Therapeutics reported promising Phase 1 clinical data for its cholesterol drug CTX310, showing significant reductions in triglycerides and LDL cholesterol levels. The data revealed dose-dependent decreases, with peak reductions of up to 82% in triglycerides and up to 86% in LDL cholesterol, alongside a well-tolerated safety profile. Barclays (LON:BARC) maintained its Equalweight rating for CRISPR Therapeutics, citing ongoing progress in its CTX310 and CTX320 programs. Meanwhile, William Blair reiterated its outperform rating, noting the competitive nature of CTX310’s LDL-C reduction results compared to similar treatments. Citizens JMP also upheld its Market Outperform rating, highlighting the potential upside as CRISPR Therapeutics advances its in-vivo pipeline. Furthermore, the company announced a delay in the CTX320 program, with data now expected in the first half of 2026 to incorporate emerging insights. Shareholders recently approved key proposals at the company’s 2025 Annual General Meeting, including amendments to the Articles of Association and the election of board members. The meeting also saw the approval of financial statements and the re-election of Ernst & Young as the company’s auditors.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.